Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
2002-11-01
2008-09-23
Wehbe, Anne Marie S (Department: 1633)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using tissue cell culture to make a protein or polypeptide
C435S326000, C435S334000, C435S455000, C435S069600, C800S018000
Reexamination Certificate
active
07427495
ABSTRACT:
The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of transplanted cells for the treatment of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.
REFERENCES:
patent: 4271145 (1981-06-01), Wands et al.
patent: 4997764 (1991-03-01), Favera
patent: 5024947 (1991-06-01), Inlow et al.
patent: 5149628 (1992-09-01), Croce
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5328844 (1994-07-01), Moore
patent: WO 92/22640 (1992-12-01), None
patent: WO 93/20200 (1993-10-01), None
Deonarain et al. (1998) Exp. Opin. Ther. Pat., vol. 8 (1), 53-69.
Miller et al. (1995) FASEB, vol. 9, 190-199.
Stites et al. (1982) Basic & Clinical Immunology, 4th Ed., Chapter 22, pp. 362-363.
Nunez et al. (1989) PNAS, vol. 86, 4589-4593.
Strasser et al. (1991) PNAS, vol. 88, 8661-8665.
Pettersson et al. (1992) Blood, vol. 79 (2), 495-502.
Anton et al., “Use of the anti-apoptotic geneBCL-2in neural transplantation,”Society for Neuroscience Abstracts19:1053 (1993).
Behl et al., “BCL-2 prevents killing of neuronal cells by glutamate but not by amyloid β protein,”Biochem.&Biophys. Res. Comm. 197:949-956 (1993).
Cheung et al., “The tyrosine kinase LCK is critically involved in the growth transformation of human B lymphocytes,”J. Biol. Chem. 266:8667-8670 (1991).
Cleary et al., “Cloning and structural analysis of cDNAs for Bcl-2 and a hybrid Bcl-2 /immunoglobulin transcript resulting from the t(14;18) translocation,”Cell47:19-28 (1986).
Clem et al., “Prevention of apoptosis by a Baculovirus gene during infection of insect cells,”Science324:1388-1390 (1991).
Coghlan, “Gene dream fades away,”New Sci. 148:14-15 (1995).
Donahue et al., “Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer,”J. Exp. Med. 176:1125-1135 (1992).
Dunphy et al., “Mitosis-inducing factors are present in a latent form during interphase in the Xenopus embryo,”J. Cell. Biol. 106:2047-2056 (1988).
Franceschi, “Cell proliferation, cell death and aging,”Aging, 1:3-15 (1989).
Garcia et al., “Prevention of programmed cell death of sympathetic neurons by the Bcl-2 proto-oncogene,”Science258:302-304 (1992).
Goodrich et al., “Abrogation by c-myc on G1 phase arrest induced by RB protein but not by p53,”Nature360:177-179 (1992).
Grogg et al., “CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC) III,”Eur. J. Immunol. 22:267-272 (1992).
Harlow and Lane,Antibodies: A Laboratory Manual(Cold Spring Harbor Laboratory, 1988), p. 203 and 277-280.
Henderson et al., “Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death,”Cell65:1107-1115 (1991).
Hockenberry et al., “Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death,”Nature348:334-336 (1990).
Huang et al., “Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells,”Science242:1563-1566 (1988).
Itoh et al., “Overexpression of bcl-2, apoptosis suppressing gene: Prolonged viable culture period of hybridoma and enhanced antibody production,”Biotechnology and Bioengineering48:118-122 (1995).
Karson et al., “Prospects for human gene therapy,”J. Rep. Med. 37:508-514 (1992).
Katsumata et al., “Differential effects of Bcl-2 on T and B cells in transgenic mice,”Proc. Natl. Acad. Sci. USA89:11376-11380 (1992).
Ledley, “Clinical considerations in the design of protocols for somatic gene therapy,”Human Gene Therapy2:77-83 (1991).
Levine et al., “Conversion of lytic to persistent alphavirus infection by the Bcl-2 cellular oncogene,”Nature361:739-742 (1993).
Marshall, “Gene therapy's growing pains,”Science269:1050,1052-1055 (1995).
McDonnell and Korsmeyer, “Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18),”Nature349:254-256 (1991).
Miyashita et al., “Bcl-2 gene transfer increases relative resistance of s49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs,”Cancer Res. 52:5407-5411 (1992).
Miyashita et al., “Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line,”Blood81:151-157 (1993).
Newmeyer et al., “Egg extracts for nuclear import and nuclear assembly reactions,”Methods in Cell Biology36:607-634 (1991).
Orkin, “Hematopoiesis: how does it happen?”Curr. Opin. Cell. Biol. 7:870-877 (1995).
Perlmutter et al., “Structure and expression of LCK transcripts in human lymphoid cells,”J. Cell. Biochem. 38:117-126 (1988).
Potter, “Neoplastic development in B-lymphocytes,”Carcinogenesis11:1-13 (1990).
Raff, “Social controls on cell survival and cell death,”Nature356:397-400 (1992).
Reed et al., “Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides,”Cancer Res. 50:6565-6570 (1990).
Schwartzman et al., “Internucleosomal deoxyribonucleic acid cleavage activity in apoptotic thymocytes: Detection and endocrine regulation,”Endocrinology128:1190-1197 (1991).
Sentman et al., “Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes,”Cell67:879-888 (1991).
Sinkovics et al., “Apoptosis by genetic engineering,”Leukemia8:98-102 (1994).
Strasser et al., “Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship,”Cell67:889-899 (1991).
Vaux et al., “Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells,”Nature335:440-442 (1988).
Vaux, “Toward an understanding of the molecular mechanisms of physiological cell death,”Proc. Natl. Acad. Sci. USA90:786-789 (1993).
Williams, “Programmed cell death: Apoptosis and oncogenesis,”Cell65:1097-1098 (1991).
Yang, “Gene transfer into mammalian somatic cells in vivo,”Critical Rev. in Biotech. 12:335-356 (1992).
Yunis et al., “Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma,”New England Journal of Medicine320:1047-1054 (1989).
Ebert et al., “A Moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig,”Mol. Endocrinol., 2(3):277-283 (1988).
Hammer et al., “Genetic engineering of mammalian embryos,”J. Anim. Sci., 63(1):269-278 (1986).
Kappel et al., “Regulating gene expression in transgenic animals,”Curr. Opin. Biotechnol., 3(5):548-553 (1992).
Strojek et al., “The use of transgenic animal techniques for livestock improvement,”Genetic Engineering: Principles and Methods, 10:221-246 (1988).
Tsujimoto et
La Jolla Cancer Research Foundation
McDermott Will & Emery LLP
Wehbe Anne Marie S
LandOfFree
Methods of using Bcl-2 for the therapeutic treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using Bcl-2 for the therapeutic treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using Bcl-2 for the therapeutic treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967972